JP2023532330A5 - - Google Patents
Info
- Publication number
- JP2023532330A5 JP2023532330A5 JP2022581465A JP2022581465A JP2023532330A5 JP 2023532330 A5 JP2023532330 A5 JP 2023532330A5 JP 2022581465 A JP2022581465 A JP 2022581465A JP 2022581465 A JP2022581465 A JP 2022581465A JP 2023532330 A5 JP2023532330 A5 JP 2023532330A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- free base
- salt
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025195295A JP2026027462A (ja) | 2020-06-30 | 2025-11-14 | ピリジン－３－カルボン酸２－［４－［（２，３，４－トリメトキシフェニル）メチル］ピペラジン－１－イル］エチルの結晶形態および合成方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063046123P | 2020-06-30 | 2020-06-30 | |
| US202063046120P | 2020-06-30 | 2020-06-30 | |
| US63/046,120 | 2020-06-30 | ||
| US63/046,123 | 2020-06-30 | ||
| PCT/US2021/039305 WO2022005928A1 (en) | 2020-06-30 | 2021-06-28 | Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin -1-yl]ethyl pyridine-3-carboxylate and methods of synthesis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025195295A Division JP2026027462A (ja) | 2020-06-30 | 2025-11-14 | ピリジン－３－カルボン酸２－［４－［（２，３，４－トリメトキシフェニル）メチル］ピペラジン－１－イル］エチルの結晶形態および合成方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023532330A JP2023532330A (ja) | 2023-07-27 |
| JP2023532330A5 true JP2023532330A5 (https=) | 2024-06-21 |
| JP7792920B2 JP7792920B2 (ja) | 2025-12-26 |
Family
ID=79314883
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022581465A Active JP7792920B2 (ja) | 2020-06-30 | 2021-06-28 | ピリジン－３－カルボン酸２－［４－［（２，３，４－トリメトキシフェニル）メチル］ピペラジン－１－イル］エチルの結晶形態および合成方法 |
| JP2025195295A Pending JP2026027462A (ja) | 2020-06-30 | 2025-11-14 | ピリジン－３－カルボン酸２－［４－［（２，３，４－トリメトキシフェニル）メチル］ピペラジン－１－イル］エチルの結晶形態および合成方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025195295A Pending JP2026027462A (ja) | 2020-06-30 | 2025-11-14 | ピリジン－３－カルボン酸２－［４－［（２，３，４－トリメトキシフェニル）メチル］ピペラジン－１－イル］エチルの結晶形態および合成方法 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4171233A4 (https=) |
| JP (2) | JP7792920B2 (https=) |
| KR (1) | KR20230031320A (https=) |
| CN (1) | CN116056711B (https=) |
| AU (1) | AU2021299266A1 (https=) |
| CA (1) | CA3188286A1 (https=) |
| IL (1) | IL299547A (https=) |
| WO (1) | WO2022005928A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023235297A1 (en) * | 2022-06-03 | 2023-12-07 | Imbria Pharmaceuticals, Inc. | Compounds and methods for increasing efficiency of cardiac metabolism |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9169279B2 (en) * | 2009-07-31 | 2015-10-27 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| CN102850296B (zh) * | 2012-09-29 | 2015-01-07 | 瑞阳制药有限公司 | 曲美他嗪的制备方法 |
| IL283725B2 (en) * | 2017-06-20 | 2024-04-01 | Imbria Pharmaceuticals Inc | Compositions and methods for increasing efficiency of cardiac metabolism |
| EP3976103A4 (en) * | 2019-05-31 | 2023-06-28 | Imbria Pharmaceuticals, Inc. | Methods of altering cardiac remodeling using compounds that promote glucose oxidation |
| EP3976101A4 (en) * | 2019-05-31 | 2023-06-21 | Imbria Pharmaceuticals, Inc. | FIBROSIS TREATMENT METHODS USING COMPOUNDS THAT PROMOTE GLUCOSE OXIDATION |
-
2021
- 2021-06-28 CA CA3188286A patent/CA3188286A1/en active Pending
- 2021-06-28 KR KR1020237003155A patent/KR20230031320A/ko active Pending
- 2021-06-28 CN CN202180056396.XA patent/CN116056711B/zh active Active
- 2021-06-28 EP EP21833175.9A patent/EP4171233A4/en active Pending
- 2021-06-28 WO PCT/US2021/039305 patent/WO2022005928A1/en not_active Ceased
- 2021-06-28 JP JP2022581465A patent/JP7792920B2/ja active Active
- 2021-06-28 IL IL299547A patent/IL299547A/en unknown
- 2021-06-28 AU AU2021299266A patent/AU2021299266A1/en active Pending
-
2025
- 2025-11-14 JP JP2025195295A patent/JP2026027462A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7174132B2 (ja) | オメカムチブメカルビルの塩及び塩を調製するプロセス | |
| JPH0647587B2 (ja) | 新規化合物、その製法及びそれを含む医薬組成物 | |
| RU2619121C2 (ru) | Форма iv ивабрадина гидрохлорида | |
| WO2003037881A1 (en) | α-FORM OR ß-FORM CRYSTAL OF ACETANILIDE DERIVATIVE | |
| JP5886869B2 (ja) | メチルフェニデート塩酸塩の低温合成 | |
| KR20080032031A (ko) | Ｏ-데스메틸벤라팍신의 결정형 | |
| JP2023532330A5 (https=) | ||
| CN117986199A (zh) | 一种枸橼酸莫沙必利杂质的合成方法 | |
| JP3215338B2 (ja) | アミノベンゼンスルホン酸誘導体一水和物及びその製造方法 | |
| JP2004520405A (ja) | 非水和塩酸フェキソフェナジンの製造方法とこの方法により得ることができる新規な結晶質形態 | |
| US10351574B2 (en) | Pharmaceutically acceptable salts and polymorphic forms of hydrocodone benzoic acid enol ester and processes for making same | |
| US10538507B2 (en) | Preparation process for high-purity dabigatran etexilate | |
| JP2004504319A (ja) | ４−フェニルピペリジン誘導体の新規製造方法 | |
| JP4866352B2 (ja) | ２−オキソ−１−ピロリジン誘導体の製造方法 | |
| JP3807938B2 (ja) | （ｒ）−（＋）−ｎ−［［３−［１−ベンゾイル−３−（３，４−ジクロロフェニル）ピペリジン−３−イル］プロプ−１−イル］−４−フェニルピペリジン−４−イル］−ｎ−メチルアセトアミド（オサネタント）の結晶フォームおよびそれらの製造法 | |
| TW434234B (en) | Amide derivatives and the pharmaceutical composition thereof | |
| WO2016132296A1 (en) | A process for the preparation of an intermediate of dabigatran etexilate | |
| EP2181982B1 (en) | Process for preparing venlafaxine hydrochloride of form I | |
| JP5530369B2 (ja) | 新規な結晶形 | |
| JPS589090B2 (ja) | 新規フエニルアミノアルカン類の製造方法 | |
| TW200412946A (en) | Synthesis of pyrrolidine derivatives and their salts | |
| JP2989059B2 (ja) | 置換アニリド | |
| TWI314929B (en) | Novel benzamide derivatives,preparation process thereof and pharmaceutical composition containing the same | |
| US20040067911A1 (en) | Isoquinuclidine derivative process for producing the same, and medicinal composition containing the same | |
| EP1366041A1 (en) | Preparation of n-methylparoxetine and related intermediate compounds |